SCHEMBL3614898

SCHEMBL3614898

COC(=O)C(NS(=O)(=O)c1ccc(-c2ccc(NC(=O)c3nc4ccccc4[nH]3)cc2)cc1)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 13/20 0.57
MMP14 P50281 5/20 0.57
MMP9 P14780 4/20 0.48
MMP13 P45452 8/20 0.48
ADAMTS4 O75173 4/20 0.48
MMP7 P09237 4/20 0.48
MMP12 P39900 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
MMP3 P08254 4/20 0.47
MMP1 P03956 3/20 0.47
MMP10 P09238 2/20 0.47
MMP8 P22894 2/20 0.47
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2381525 0.91 MMP2 (0.69) MMP2MMP14MMP9MMP13ADAMTS4
SCHEMBL12247611 0.91 MMP2 (0.69) MMP2MMP14MMP9MMP13ADAMTS4
SCHEMBL12684676 0.91 MMP2 (0.69) MMP2MMP14MMP9MMP13ADAMTS4
SCHEMBL3613259 0.81 NPC1 (0.58) MMP2MMP14MMP9MMP13ADAMTS4
SCHEMBL3610818 0.80 ADAMTS4 (0.48) MMP2MMP14MMP9MMP13ADAMTS4
SCHEMBL12808878 0.76 MMP2 (0.76) MMP2MMP14MMP9MMP13ADAMTS4
SCHEMBL3614367 0.75 MMP2 (0.82) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL3610779 0.75 MMP2 (0.82) MMP2MMP14MMP13ADAMTS4MMP7
SCHEMBL3611082 0.73 MMP2 (0.54) MMP2MMP14MMP9MMP13ADAMTS4
SCHEMBL3611088 0.73 MMP2 (0.54) MMP2MMP14MMP9MMP13ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same WYETH (US) 2010-06-03 US disclosed
EP-1692124-B1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH CORP (US) 2008-10-15 EP disclosed
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US disclosed
EP-1692124-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS Wyeth (US) 2006-08-23 EP disclosed
WO-2005061477-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH (US) 2005-07-07 WO disclosed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same STS, MMP3, AADAC MMP2 5/4885MMP14 19/4885MMP9 14/4885
US-20050143422-A1 Biaryl sulfonamides and methods for using same STS, MMP3, AADAC MMP2 5/4885MMP14 19/4885MMP9 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.